Work

Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.2053

Authors: Andrew David Norden, David Schiff, Manmeet Singh Ahluwalia, Glenn Jay Lesser, Lakshmi Nayak, Eudocia Quant Lee, Mikael L. Rinne, Alona Muzikansky, Jorg Dietrich, Benjamin Purow, Katrina H. Smith, Sarah C. Gaffey, Christine Sceppa McCluskey, Keith L. Ligon, David A. Reardon, Patrick Y. Wen

Institutions: Dana-Farber Cancer Institute, University of Virginia Medical Center, Cleveland Clinic, Wake Forest University Health Sciences, Wake Forest University, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, University of Virginia, Brigham and Women's Hospital, Boston Children's Hospital

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2598376382

Cites:

Cited by: 2

Related to: 10